Quantitative T1 brain mapping in early relapsing-remitting multiple sclerosis: longitudinal changes, lesion heterogeneity and disability

Category	Detail
Condition	Relapsing-Remitting Multiple Sclerosis (RRMS)
Key Mechanisms	Episodic immune-mediated demyelination causing axonal damage and neuronal dysfunction; T1 prolongation reflecting myelin density loss and microstructural tissue damage
Target Population	Adults recently diagnosed with RRMS (<6 months from diagnosis)
Care Setting	Neurology clinics with access to advanced MRI imaging facilities

T1-weighted hypointense lesions ('black holes') indicate more severe white matter damage and correlate with worse disability.
Quantitative T1 mapping provides a sensitive, non-invasive marker of myelin density and microstructural heterogeneity within lesions and normal-appearing brain tissue.
T1 prolongation in white matter lesions and other brain regions correlates with clinical disability and may progress over the first year after RRMS diagnosis.

Use MRI including T2-weighted FLAIR and T1-weighted sequences to identify new or enlarging white matter lesions.
Consider quantitative T1 mapping to assess microstructural tissue integrity and heterogeneity within lesions and normal-appearing brain tissue.

Early identification of lesion characteristics via T1 mapping may inform prognosis and guide treatment decisions.
Avoid prior disease-modifying therapies before baseline imaging to ensure accurate assessment of disease activity.

Perform longitudinal MRI including T1 mapping at baseline and 1-year follow-up to track lesion evolution and tissue integrity changes.
Use Expanded Disability Status Scale (EDSS) scores alongside imaging to monitor clinical disability progression.

MRI contraindications should be assessed prior to imaging.
Interpretation of T1 hypointensity should consider potential subjectivity and complement quantitative measures.

Recently diagnosed RRMS patients naïve to disease-modifying therapies

Quantitative T1 mapping may help predict clinical disability trajectory and guide early treatment initiation.

Obtain informed consent and ensure ethical compliance for MRI studies.
Use standardized MRI protocols including 3-Tesla scanners and validated sequences for T1 mapping.
Apply automated and manual lesion segmentation methods to accurately delineate white matter lesions.
Incorporate test-retest reliability assessments to validate T1 mapping measures.
Integrate imaging findings with clinical disability scales for comprehensive patient evaluation.

Clinical Scorecard: Longitudinal Analysis of T1 Brain Mapping in Early Relapsing-Remitting Multiple Sclerosis: Variability in Lesion Characteristics and Associated Disability